Aspartame Causes Developmental Defects and Teratogenicity in Zebra Fish Embryo: Role of Impaired SIRT1/FOXO3a Axis in Neuron CellsArticle Published on 2024-04-122024-09-05 Journal: Biomedicines [Category] update2024, [키워드] aspartame neurodevelopment SIRT1/FOXO3a axis teratogenicity zebrafish embryos [DOI] 10.3390/biomedicines12040855 PMC 바로가기 [Article Type] Article
Assessment of the scope, completeness, and consistency of various drug information resources related to COVID-19 medications in pregnancy and lactationarticle Published on 2023-04-272024-09-05 Journal: BMC Pregnancy and Childbirth [Category] update2024, [키워드] Consistency Evidence-based information Fetal risk medication information teratogenicity treatment guidelines [DOI] 10.1186/s12884-023-05609-2 PMC 바로가기 [Article Type] article
Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5′-triphosphate exposure to support posology for SARS-CoV-2SARS-CoV-2에 대한 용법을 뒷받침하기 위한 세포 내 favipiravir ribofuranosyl-5'-triphosphate 노출을 추정하기 위한 약동학 모델링Original Research Published on 2021-08-022022-09-10 Journal: Journal of Antimicrobial Chemotherapy [Category] SARS, 치료제, [키워드] Analysis Antiviral approach available data canine Cell Chinese patient Chinese patients clearance Combination Concentration consolidation Course described dosing interval driven by dynamic range Elimination estimate Favipiravir in vitro in vitro data indicate kidney Loading dose mathematical mathematical model metabolite objective optimal dose parent pharmacokinetic plasma plasma concentration polymerase Population mean predict predicted regimen Result SARS-CoV-2 Support teratogenicity the SARS-CoV-2 trough [DOI] 10.1093/jac/dkab135 PMC 바로가기 [Article Type] Original Research
Suspected cholestatic liver injury induced by favipiravir in a patient with COVID-19COVID-19 환자에서 favipiravir에 의해 유발된 담즙정체성 간 손상 의심Case Reports Published on 2021-02-012022-09-11 Journal: Journal of infection and chemotherapy : official j [Category] SARS, 치료제, [키워드] addition Administered alcoholic hepatitis Antibiotics Antimicrobial therapy antiviral drug Bacterial bacterial pneumonia Bilirubin Cholestasic Complication Deterioration drug therapy elevated expected extracorporeal membrane oxygenation Favipiravir Hepatitis High dose Hyperuricemia impaired liver function interferon Japanese liver dysfunction Liver function Liver injury Lopinavir Lopinavir/ritonavir monitoring Patient patient with COVID-19 Pneumonia promoted Ritonavir SARS-CoV2 SARS-CoV2 infection Side effect Side effects subsequent Support Suspected teratogenicity therapeutic effect total bilirubin transaminase Treatment triggered veno-venous extracorporeal membrane oxygenation worsened [DOI] 10.1016/j.jiac.2020.12.021 PMC 바로가기 [Article Type] Case Reports
A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic?Review article Published on 2020-04-012022-10-05 Journal: Journal of Virus Eradication [Category] 신약개발, 치료법, [키워드] 2019 coronavirus disease adverse event AEs Analysis Antiviral Arm ARMS broad-spectrum antiviral comparator conducted COVID-19 drug Ebola Effect Elevation Evidence examined Favipiravir Follow-up for inclusion gastrointestinal AE Human indicated Influenza limitation oseltamivir pandemic Participants Placebo Potential treatment proportion QTC prolongation representing repurposing Result Safe safety profile serious AE serious AEs shown significantly significantly more Specific statistical teratogenicity tolerable Treatment Trial umifenovir uric acid widespread [DOI] 10.1016/S2055-6640(20)30016-9 [Article Type] Review article
Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19Review article Published on 2020-04-012022-10-05 Journal: Journal of Virus Eradication [Category] 신약개발, [키워드] accounted acute infection acute respiratory syndrome adjusted AEs Analysis approved calculate Clinical studies Concentration conducted coronavirus coronavirus disease Course COVID-19 COVID-19 patient database demonstrated dosages dose doses drug drugs EC50 Effects Efficacy Endpoint Evidence for inclusion in vitro India ingredient inhibit initiated margin Metrics nitazoxanide pandemic participant per day pharmacies Placebo Placebo-controlled trials plasma concentration Potential treatment promote raised randomised controlled trial RCT RCTs Replication reported required Research Result review Safe safety profile SARS-CoV-2 searched Serious Adverse Event shown significant difference teratogenic teratogenicity treat Treatment treatments for COVID-19 Trial trials [DOI] 10.1016/S2055-6640(20)30017-0 [Article Type] Review article